A winner is crowned in head-to-head Alzheimer’s battle between Biogen’s Aduhelm and Lilly – Dec 1, 2022
Eli Lilly CEO David Ricks was confident last year that donanemab would best Biogen and Eisai’s approved Alzheimer’s disease drug in a head-to-head battle. Now, the results are in—and Ricks was right.
In a trial comparing the two therapies, donanemab reduced brain amyloid plaque levels by 65.2% at six months compared to baseline, while Aduhelm reduced levels by 17% for the same time period. The donanemab data, which were shared Nov. 30 at the Clinical Trials on Alzheimer’s Disease conference, comes from Lilly’s ongoing phase 3 study, dubbed TRAILBLAZER-ALZ 4.
Lilly powers through final stretch in critical Alzheimer’s race – Nov 1, 2022
Following Eisai’s (Biogen) successful phase 3 readout of its Alzheimer’s disease treatment lecanemab, the pressure—and optimism—is mounting for top competitor Eli Lilly.
On the company’s third-quarter earnings call Tuesday, executives heralded those results, which found a 27% reduction in clinical decline among treated patients with early Alzheimer’s, as providing additional validation of the amyloid beta hypothesis that’s driven the development of Lilly’s own donanemab.
Eli Lilly takes to social media for a personal touch to its Alzheimer’s campaign (April 2022)
Eli Lilly is sitting on a potential $6 billion a year Alzheimer’s drug in donanemab, according to Evaluate Pharma, which could grab FDA approval next year. But one only needs to look over at rival Biogen—which won an accelerated U.S. approval for its similar Alzheimer’s drug, Aduhelm, last year—to see how tough a sell this could be.
October 2021
